Bristol Myers Squibb received FDA breakthrough therapy status for its drug iza-bren, advancing development outside of China licensing.
2 reports, 2 independent
Updated Aug 20
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bristol Myers Squibb received FDA breakthrough therapy status for its drug iza-bren, advancing development outside of China licensing.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.
- Bristol-Myers Squibb holds exclusive commercial rights in Japan after the FDA accepted Zenas's Biologics License Application.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyFDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug Bristol Myers Squibb and SystImmune have announced breakthrough therapy designation from the US Food and Drug Administration
- PR NewswireIzalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer First Breakthrough T